David Shaywitz

One consequence of the present crisis is the urgent embrace of telemedicine, as I recently discussed. Whether the adoption is sustained beyond the crisis period remains to be determined, although use seemed to be increasing overall even before the pandemic hit.  As more physicians and patients find themselves pressed to adopt telemedicine, I thought it might be helpful to better... Read More

This week, I reviewed for the Wall Street Journal a pair of books about the increasing use of experimentation by businesses and other organizations: Experimentation Works, by Harvard Business School professor Stefan Thomke, and The Power of Experiments, by Michael Luca and Max Bazerman, also of Harvard Business School.  These books in some ways represent the sequel to one of... Read More

Technology companies are experiencing a staggering reversal of reputational (though not financial) fortune; their stature seems reduced with each successive news cycle.  Gone is the halo many tech companies once enjoyed. The implicit (and often explicit) assumption that tech innovation inevitably makes the world a better place has been replaced by real concerns that the picture may be far more... Read More

Digital transformation (as I recently discussed), and the implementation of emerging technologies more generally, is routinely pitched by enthusiasts like Tom Siebel as both urgent and inevitable, something organizations need to embrace or risk irrelevance, if not extinction.  Yet the “embrace or die” assertion is under increasing, and healthy, scrutiny, as the “techlash” (technology backlash) gains steam.  “Surveillance Capitalism”: Tech... Read More

I had the privilege of serving as emcee for the “Data Science and AI” track on the first day of this week’s Precision Medicine World Conference (PMWC) in Santa Clara, CA, as well as chairing a panel discussion on data mining and visualization.  I came away with a sense of optimism and need, organized around several key themes. In Praise... Read More

The phrase resounding in corporations these days is “digital transformation.” What does that really mean? According to proponents, digital transformation reflects the assertion that in order to remain competitive in the modern era, organizations need to radically rethink their approach to how they collect, manage, and analyze information.  Change is clearly afoot, but the ideology informing this hasn’t been entirely... Read More

Pharma innovation expert Bernard Munos captures the inherent inefficiency of drug development with two fascinating statistics he recently shared with me.  First, for large pharmas, the average cost of developing a new drug (simply based on the total R&D costs divided by the total number of new drugs approved for sale) works out to about $5B per drug. It’s an... Read More

With the New Year, I’m very excited to share a professional update: as of January 1, I’m the proud founder of “Astounding HealthTech,” providing advisory services to R&D-driven biopharma organizations and health tech startups striving to engage each other more effectively. The mission of Astounding is to catalyze drug development by aligning the specific capabilities and distinct needs of individual... Read More

Last year, at about this time, I shared my experience losing 80 pounds. I achieved this goal through a low-carb diet and coaching, guided by the Virta program, along with regular exercise. The overarching concern I expressed in that article, one year ago, was my recognition of how fragile weight loss can be. Most people who lose significant weight soon gain it... Read More

I listen to a lot of audio, spoken word content that edifies (or at least distracts) me during daily workouts and when traveling.  Traditionally in December, I like to share with readers my annual podcast recommendations. But in reflecting on my listening habits of the last year, I realized that I’ve probably spent at least as much time listening to... Read More

Biopharmaceutical and healthcare executives increasingly find themselves attending conferences and presentations featuring the evangelistic selling of AI by self-assured VCs, energetic entrepreneurs, and earnest consultants.  The promise is that AI will change everything. Then the executives return to work, face the quotidian reality of their operation, and wonder whether AI will change anything. Enter Jim Manzi. Manzi, depending on your view, is a... Read More

Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant... Read More

[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech... Read More